Actively Recruiting
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
Led by M.D. Anderson Cancer Center · Updated on 2026-04-15
54
Participants Needed
1
Research Sites
246 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To find the highest tolerable dose of IACS-6274 that can be given alone, in combination with bevacizumab and paclitaxel, or in combination with capivasertib to patients who have solid tumors. The safety and tolerability of the study drug(s) will also be studied.
CONDITIONS
Official Title
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Written informed consent provided
- Male or female patients aged 18 years or older
- Histologically or cytologically confirmed advanced solid tumors including specific mutations or cancer subtypes as defined for each study part
- Received at least one line of therapy for advanced disease and refractory or ineligible to existing treatments
- Completed prior chemotherapy, radiotherapy, immunotherapy, or investigational therapies at least 3 weeks before study drug with resolved or stable side effects
- Available fresh or archival tumor tissue for biomarker analysis
- At least one measurable or non-measurable lesion suitable for repeated assessment
- ECOG performance status of 0 or 1 with no recent deterioration
- Adequate organ function based on specific blood counts, kidney, liver, and cardiac function
- Female patients of non-childbearing potential or using effective contraception if of childbearing potential
- Male patients who agree to use contraception or abstain from sexual activity as specified
You will not qualify if you...
- Prior malignancy within 2 years except certain cured cancers
- Primary central nervous system malignancy or symptomatic brain metastases (unless stable and off steroids)
- Uncontrolled or significant recent cardiac conditions including unstable arrhythmia, prolonged QT interval, recent heart attack or severe heart failure
- Major surgery within 28 days before study drug or planned during study
- Significant acute or chronic infections
- Psychiatric conditions preventing informed consent
- Use of strong CYP3A4 or CYP2D6 interacting drugs shortly before study
- Recent radiotherapy within 4 weeks (with exceptions)
- Severe or uncontrolled systemic diseases or bleeding risk
- Allergic reactions to study drug components
- History of alcohol or drug abuse
- Inability to swallow oral medication properly
- Unwillingness to comply with study protocol
- Other conditions posing high risk or interfering with study as judged by investigator
- Part B specific: severe hypersensitivity to monoclonal antibodies, paclitaxel, or bevacizumab; bowel obstruction history; significant proteinuria; increased bleeding risk; significant cardiovascular disease; peripheral neuropathy grade 2 or higher; recent paracentesis
- Part C specific: other primary malignancy within 5 years; hypersensitivity to capivasertib; diabetes with poor control; severe liver disease or abnormal liver tests; persistent toxicities from prior therapy; spinal cord compression or leptomeningeal disease needing steroids; significant cardiovascular disease or related abnormalities; active tuberculosis or hepatitis infections; HIV with uncontrolled viral load or recent AIDS infections; concurrent anticancer treatments; recent palliative or extensive radiotherapy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
M D Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
Research Team
T
Timothy A Yap, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here